Extracorporeal Membrane Oxygenation Retrieval in Coronavirus Disease 2019: A Case-Series of 19 Patients Supported at a High-Volume Extracorporeal Membrane Oxygenation Center

Jordi Riera, PhD1–3; Eduard Argudo, MD1,2; María Martínez-Martínez, MD1,2; Sandra García, MD1,2; Marina García-de-Acilu, MD1,2; Manel Santañé, MD1,2; Cándido Díaz, PhD1,2; Sofía Contreras, MD1,2; Alexandra Cortina, MD1,2; Camilo Bonilla, MD1,2; Andrés Pacheco, MD1,2; Paula Resta, MD4; Neiser Palmer, PhD4; Miguel Ángel Castro, MD4; Ricard Ferrer, PhD1–3

Objective: To evaluate the performance of the extracorporeal membrane oxygenation retrieval team at a high-volume extracorporeal membrane oxygenation center during the coronavirus disease 2019 pandemic.

Design: Observational study including all adult patients with confirmed infection due to severe acute respiratory syndrome coronavirus-2 cannulated at other centers and transported on extracorporeal membrane oxygenation to the ICU of the Vall d’Hebron University Hospital between 15 March and 10 June 2020.

Setting: The ICU (capacity expanded to 200 during the pandemic) of the Vall d’Hebron University Hospital (a 1,100-bed public university hospital in Barcelona), the referral center for extracorporeal respiratory support in Catalonia (7.5 million inhabitants).

Patients: Extracorporeal membrane oxygenation was considered if the $\text{PaO}_2/\text{FiO}_2$ ratio less than 80 mm Hg (refractory to prone position) and/or $\text{Paco}_2$ greater than 80 mm Hg and pH less than 7.25 for more than 6 hours, and no contraindications for extracorporeal support were present.

Interventions: Venovenous extracorporeal membrane oxygenation was initiated in the primary center. Then, patients were transferred to the ICU of the Vall d’Hebron University Hospital where they received support until respiratory improvement. After decannulation, patients were discharged for rehabilitation at the primary center.

Measurements and Main Results: Nineteen patients with severe acute respiratory syndrome coronavirus-2 infection and with a mean $\text{PaO}_2/\text{FiO}_2$ ratio of 71 mm Hg (57–118 mm Hg) despite prone positioning and a mean $\text{Paco}_2$ of 70 mm Hg (47–110 mm Hg) were transferred to our center from their primary hospital after cannulation and received venovenous extracorporeal membrane oxygenation support. Prior to cannulation, six patients (31.5%) presented vascular thrombosis, and nine (47.4%) were already receiving anticoagulant therapy. Eighteen transfers were carried out with no significant complications. While on extracorporeal membrane oxygenation, thrombotic events were recorded in nine patients (47.4%) and hemorrhagic events in 13 (68.4%). Thirteen patients (68.4%) were successfully weaned, and 12 (63.1%) were discharged home.

Conclusions: Extracorporeal membrane oxygenation retrieval can rescue young, previously healthy patients with severe coronavirus disease 2019 in whom all the conventional respiratory measures have failed. Thrombotic and hemorrhagic complications are frequent in this cohort.

Key Words: coronavirus; coronavirus disease 2019; extracorporeal membrane oxygenation; extracorporeal membrane oxygenation retrieval; extracorporeal membrane oxygenation transport; severe acute respiratory syndrome coronavirus 2

1Department of Critical Care, Vall d’Hebron University Hospital, Barcelona, Spain.
2SODIR, Vall d’Hebron Research Institute, Barcelona, Spain.
3CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
4Department of Cardiac Surgery, Vall d’Hebron University Hospital, Barcelona, Spain.

Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Crit Care Expl 2020; 2:e0228
DOI: 10.1097/CCE.0000000000000228
significant percentage of critically ill patients with the coronavirus disease 2019 (COVID-19) may develop hypoxemia and/or respiratory acidosis that are refractory to conventional measures including prone positioning. Extracorporeal membrane oxygenation (ECMO) in its venovenous configuration has been shown to be effective in improving gas exchange while allowing a reduction in the mechanical power delivered by mechanical ventilation (MV) in the most severe cases of respiratory failure (1). The results of the first published reports of the use of ECMO in COVID-19 were discouraging (2–8); however, in those studies, key specific data about patient selection and specific management directly related with outcomes after ECMO are lacking. Further, although the concentration of patients at high-volume ECMO centers has been associated with better outcomes (9), there are no published data available regarding the feasibility of ECMO retrieval of patients with COVID-19.

In the present case series, we describe the activity of the ECMO retrieval team at a regional high-volume ECMO reference center during this pandemic period, focusing on the clinical characteristics of the patients, ECMO management, and outcomes. We also provide details of the activations that were requested but finally rejected.

MATERIALS AND METHODS

A retrospective analysis was performed of the prospectively recorded data of all the adult patients with confirmed infection due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cannulated at other centers and transported on ECMO to the Vall d’Hebron University Hospital (VHUH) between 15 March and 15 June. Data from all the other activations of the ECMO retrieval team in this period were also recorded and analyzed.

The VHUH is a 1,100-bed public university hospital in Barcelona with a 54-bed ICU. The ICU capacity was expanded to 200 during the pandemic, and in all, more than 300 critically ill COVID-19 patients were admitted. Criteria for ECMO team activation were a ratio of Pao2 to the Fio2 less than 80 mm Hg, refractory to prone positioning (defined by a ratio increase of < 20% after at least 12 hr), and/or a Paco2 greater than 80 mm Hg and respiratory acidosis: 2 (10.5) mm Hg (57–118 mm Hg) despite prone positioning. Respiratory acidosis was also common (Paco2 of 70 mm Hg [47–110 mm Hg]), and the mechanical power delivered to the respiratory system was high. In 11 cases (57.9%), the team had no information about vessel diameter prior VHUH departure due to the impossibility of placing the proned patient in the supine position because of life-threatening respiratory deterioration when mobilized to this position.

Cannulation, Transport, and ECMO Management

Significant information on cannulation, transport, and ECMO management is summarized in Table 2. Prior to cannulation,

| Variables                              | Mean (Range) or n (%) |
|----------------------------------------|-----------------------|
| Age, yr                                | 50.5 (31–64)          |
| Gender, male                           | 16 (84.2)             |
| Hypertension                           | 7 (36.8)              |
| Body mass index, kg/m²                 | 31.9 (22.2–40.8)      |
| Days since intubation                  | 8.6 (0–17)            |
| Indication                             | Refractory hypoxemia: 17 (89.5); refractory respiratory acidosis: 2 (10.5) |
| Pao2/Fio2 at cannulation, mm Hg        | 70.8 (57–118)         |
| pH at cannulation                      | 7.2 (6.9–7.4)         |
| Paco2 at cannulation, mm Hg            | 70.4 (47–110)         |
| Positive end-expiratory pressure at cannulation, cm H₂O | 11.2 (6–17) |
| Tidal volume at cannulation, mL        | 410 (280–500)         |
| Driving pressure, cm H₂O               | 24.4 (20–30)          |
| Respiratory rate at cannulation, beats/ min | 28 (22–38) |
| Prone before ECMO                      | 19 (100)              |
| Inhaled nitric oxide before ECMO       | 1 (5.2)               |
| Neuromuscular blockade before ECMO     | 19 (100)              |
| Imposibility to place the patient supine before arrival of the ECMO team | 11 (57.9) |

ECMO = extracorporeal membrane oxygenation.

Continuous variables are expressed as means (ranges) and categorical variables as n (%).
vascular thrombosis was present in six patients (31.5%), and almost half of the cohort (47.4%) received anticoagulation. The femoro-femoral approach was the most common cannulation strategy (78.9%), and a mean drainage diameter of 24.5F (23–25F) allowed a mean ECMO flow of 4 L/min despite daily negative fluid balance. Ground transport (ambulance) was used in all the services. There were no (or only minor) complications during transport, except in one case in which pulseless electrical activity (PEA) was evidenced, resulting in death despite conversion to extracorporeal cardiopulmonary resuscitation. The cardiac rhythm, the stability of hemoglobin and electrolytes the absence of pericardial occupation, and presence of dilated right ventricle in the echocardiography made us hypothesize that the cardiac arrest was secondary to a massive pulmonary thromboembolism.

As soon as extracorporeal support was initiated, the mechanical power delivered to the respiratory system was notably decreased (mean inspiratory pressure of 12.1 cm H2O [10–14.5 cm H2O] and respiratory rate of 11.6 breaths/min [10–14 breaths/min]). During ECMO support, a mean of 2.5 (0–7) fiberbronchoscopies and 0.6 (0–3) CT per patient were performed. Four patients (21%) needed continuous renal replacement therapy and three (15.7%) extracorporeal cytokine hemoadsorption.

All the patients received heparin infusion, with a daily mean of activated clotting time of 156.4 seconds (128–181.3 s). Despite this, thrombotic events were detected in nine patients (47.4%), with six (31.5%) being diagnosed of deep venous thrombosis and five (26.3%) needing circuit change. Hemorrhagic events were identified in 13 patients (68.4%), five of them needing surgery or embolization. Regarding the site of bleeding, seven patients (36.8%) suffered airways and/or lung hemorrhage, three (15.7%) cannula-related bleeding, two (10.5%) gastrointestinal blood loss, and one (5.2%) hematuria. No thrombotic or hemorrhagic complications were directly associated with patient death.

Outcomes
By 15 June, 68.4% of the patients had been successfully weaned and discharged to their primary center, 10.5% were still on ECMO, and 21.1% had died despite the support (Table 3). At that time, 92.3% of weaned patients were breathing spontaneously, with no respiratory support, and only one patient was still in the

---

**TABLE 2. Cannulation, Transport, and Extracorporeal Membrane Oxygenation Management**

| Variables                        | Mean (Range) or n (%) |
|----------------------------------|-----------------------|
| Vascular thrombosis prior to cannulation | 6 (31.5)             |
| Patient anticoagulated prior to cannulation | 9 (47.4)             |
| ECMO configuration                | Venovenous: 19 (100)  |
| Cannulation strategy              | LFV to RFV: 14 (73.7); LFV to RJV: 3 (15.7); RFV to RJV: 1 (5.3); RFV to LFV: 1 (5.3) |
| Distance between primary center and Vall d'Hebron University Hospital, km | 33.8 (5–160)         |
| Duration of service, hr           | 5.6 (3.5–8.5)         |
| Life-threatening complications during transport | 1 (5.2)             |
| Minor complications during transport | Flow fluctuations: 4 (21); peripheral oxygen saturation < 85%: 2 (10.5) |
| ECMO flow during transport, L/min | 4 (3.5–4.8)           |
| ECMO flow at ICU, L/min           | 3.9 (3.4–4.8)         |
| Inspiratory pressure during ECMO, cm H2O | 12.1 (10–14.5)       |
| Respiratory rate during ECMO, breaths/min | 11.6 (10–14)         |
| Fiberbronchoscopy performed while on ECMO | 2.5 (0–7)           |
| CT performed while on ECMO        | 0.6 (0–3)             |
| Patients with thrombotic complications while on ECMO | 9 (47.4)             |
| Patients with hemorrhagic complications while on ECMO | 13 (68.4)             |
| Patients with renal failure requiring continuous renal replacement therapy | 4 (21)             |
| Patients with cytokine hemoadsorption | 3 (15.7)             |

**TABLE 3. Outcomes After Extracorporeal Membrane Oxygenation Support Evaluated on 15 June**

| Variables                        | Mean (Range) or n (%) |
|----------------------------------|-----------------------|
| ECMO status                      | Weaned: 13 (68.4); ongoing: 2 (10.5); deceased: 4 (21.1) |
| Respiratory status of weaned patients | No support: 12 (92.3); mechanical ventilation weaning process: 1 (7.7) |
| Alive patients needing percutaneous tracheostomy | 15 (100)             |
| ECMO days of weaned patients     | 10.7 (2–33)           |
| Patients discharged from Vall d’Hebron University Hospital for rehabilitation | 13 (68.4)             |
| Patients discharged home         | 12 (63.1)             |

ECMO = extracorporeal membrane oxygenation, LFV = left femoral vein, RFV = right femoral vein, RJV = right jugular vein.
Continuous variables are expressed as means (ranges) and categorical variables as n (%). Except in one case in which pulseless electrical activity (PEA) was evidenced, resulting in death despite conversion to extracorporeal cardiopulmonary resuscitation. The cardiac rhythm, the stability of hemoglobin and electrolytes the absence of pericardial occupation, and presence of dilated right ventricle in the echocardiography made us hypothesize that the cardiac arrest was secondary to a massive pulmonary thromboembolism.

As soon as extracorporeal support was initiated, the mechanical power delivered to the respiratory system was notably decreased (mean inspiratory pressure of 12.1 cm H2O [10–14.5 cm H2O] and respiratory rate of 11.6 breaths/min [10–14 breaths/min]). During ECMO support, a mean of 2.5 (0–7) fiberbronchoscopies and 0.6 (0–3) CT per patient were performed. Four patients (21%) needed continuous renal replacement therapy and three (15.7%) extracorporeal cytokine hemoadsorption.

All the patients received heparin infusion, with a daily mean of activated clotting time of 156.4 seconds (128–181.3 s). Despite this, thrombotic events were detected in nine patients (47.4%), with six (31.5%) being diagnosed of deep venous thrombosis and five (26.3%) needing circuit change. Hemorrhagic events were identified in 13 patients (68.4%), five of them needing surgery or embolization. Regarding the site of bleeding, seven patients (36.8%) suffered airways and/or lung hemorrhage, three (15.7%) cannula-related bleeding, two (10.5%) gastrointestinal blood loss, and one (5.2%) hematuria. No thrombotic or hemorrhagic complications were directly associated with patient death.

Outcomes
By 15 June, 68.4% of the patients had been successfully weaned and discharged to their primary center, 10.5% were still on ECMO, and 21.1% had died despite the support (Table 3). At that time, 92.3% of weaned patients were breathing spontaneously, with no respiratory support, and only one patient was still in the
process of MV weaning. In all, 63.1% of the patients were discharged home.

**Other VHUH ECMO Retrieval Team Activations**

In the same period, the team received 41 other calls from 18 centers. More hours of prone positioning were suggested in 41.4% of cases and changes in MV variables in 12.2%. ECMO contraindications were found in 46.3%, advanced age being the most common (68.4%). Other frequent contraindications were long time on MV (19.5%), immunosuppression (7.3%), and morbid obesity (7.3%).

**DISCUSSION**

This is the largest published report of ECMO retrieval of patients with severe COVID-19 disease. More than two thirds of the patients were successfully weaned, and 63.1% could be discharged home.

Life-threatening complications may occur during ECMO transport. Furthermore, transporting patients with SARS-CoV-2 infection is particularly difficult due to the characteristics of the disease and also due to the requirement of operator protection for contagion (9). In our series, 18 of 19 ECMO transports occurred with no significant incidents. One patient developed PEA during transport, probably due to pulmonary embolism and subsequently died. Other difficulties that we encountered included anticoagulation prior to cannulation, previous venous thrombosis, and lack of information on vein diameter due to the impossibility of placing the patient in the supine position, but, in our series, they did not complicate the performance of the technique.

Only four of 19 patients died on ECMO, a low rate compared with most of the reports in the literature of its use in patients with COVID-19 (2–8). However, those publications report very short series or compilations of small numbers of cases at many different centers. It has been shown that concentrating ECMO cases in high-volume centers markedly improves outcomes (10). A recently published experience of 17 patients supported with ECMO in a French high-volume ECMO center reported a 58.9% ICU survival at 60 days, similar to our figures (11). They also report frequent thrombotic and hemorrhagic events. There are other circumstances that may explain our positive results. First, ECMO allowed a significant decrease in the mechanical power applied to the lungs, which has been shown to be associated with better outcomes in patients with acute respiratory distress syndrome (ARDS) (12). In our series, it was possible to substantially reduce the inspiratory pressure, together with the respiratory rate, after the initiation of extracorporeal support. Further, certain diagnostic and therapeutic maneuvers that are life-threatening with MV support alone could be safely performed with ECMO. We performed fiberbronchoscopy with secretion clearance and microbiological surveillance in most patients, in many cases on a daily basis, which helped to improve respiratory evolution and antibiotic therapy titration. ECMO also allowed the in-hospital transport of patients to the CT scan. Images helped clinicians to adjust treatment and better evaluate the evolution of the lung disease.

Thrombotic and hemorrhagic complications in our cohort were frequent. In fact, the circuit had to be changed in five patients. This is to be expected, since COVID-19 has been associated with coagulation disorders that might be exacerbated by the extracorporeal system (13). Interestingly, these complications did not have a direct impact on mortality: possible reasons for this include the careful VHUH ECMO team training, the centralization of patients in the same unit, the adequate nurse-patient ratio, and the use of updated anticoagulation management protocols.

The uncertainties surrounding the evolution of COVID-19 disease and prognosis of these very severe ARDS patients, together with the association of ECMO with high resource consumption, mean that the decision to indicate the technique is particularly difficult. In fact, we ruled out 41 activations proposed by the ECMO retrieval team during the study period, either on the grounds that the respiratory condition was not sufficiently severe to benefit from the technique or due to the presence of contraindications that made the indication of ECMO futile. The most common reason for ruling out ECMO was advanced age. The exact cut-off point for age is a matter of debate, but sufficient evidence is available to show that mortality in ECMO increases in the older population.

The single-center design of this report may be considered as a limitation. However, ECMO management and protocols vary widely between centers. This variability may alter the conclusions obtained regarding the usefulness of the technique in patients with COVID-19, and in fact, we see this as a weakness of previously published articles which include small numbers of cases from many different centers (4–6, 14, 15). Although the sample in this observational study is one of the largest published to date (19 patients), it is not large enough to allow any definitive conclusions to be drawn.

**CONCLUSIONS**

In spite of this limitation, this study shows that ECMO retrieval by an experienced team can rescue young, previously healthy patients with severe COVID-19 in whom all conventional respiratory measures have failed. Thrombotic and hemorrhagic complications are frequent in this cohort.

**ACKNOWLEDGMENTS**

We thank the following members for their support: 1) Critical Care Department: Vall d’Hebron University Hospital: Jesús Martínez, MD, PhD; Xavier Nuvials, MD, PhD; Juan Carlos Ruiz-Rodríguez, MD, PhD; Rosa María Gracia, MD, PhD; Judit Sacanell, MD; César Laborda, MD; Marcos Pérez, MD, PhD; Oriol Roca, MD, PhD; Raquel Albertos, MD; Anna Sánchez, MD; Elisabet Papiol, MD; Adolf Ruíz, MD; Mónica Díaz, MD; Alejandro Cortés, MD; Manuel Sosa, MD; Luis Chiscano, MD; Claudia Vizcaíno, MD; Berta Caralt, MD; Álvaro Garcia, MD; Maria Carrasco, MD, PhD; Xavier Peris, MD; Asunción Torrents, MD; Cristopher Mazo, MD; Aroa Gómez, MD; Abrahán Mera, MD; Elisabet Gallart, Pilar Girón, Carme Durà, Montserrat Aran,Montserrat Guillen, Miriam Mey, Samuel Carmona, Marta Juvanteny, Laura Planas, Antonio López. 2) Cardiac Surgery Department: Vall d’Hebron University Hospital: Rafael Rodríguez-Lechoq, MD, PhD; Carles Sureda, MD; María Sol, MD; Remedios Ríos, MD. 3) Cardiology Department: Germans Trias i Pujol University Hospital: Omar Abdul-Jawad Altisen, MD, PhD. 4) Critical Care Department: Santa Creu i Sant Pau University Hospital: Jordi Mancebo, MD,
REFERENCES

1. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR trial collaboration: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet 2009; 374:1351–1363

2. Henry BM, Lippi G: Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J Crit Care 2020; 58:27–28

3. Zeng Y, Cai Z, Xianyu Y, et al: Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: A retrospective case series. Crit Care 2020; 24:148

4. Li X, Guo Z, Li B, et al: Extracorporeal membrane oxygenation for Coronavirus disease 2019 in Shanghai, China. ASAIO J 2020; 66:475–481

5. Ruan Q, Yang K, Wang W, et al: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46:846–848

6. Yang X, Yu Y, Xu J, et al: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475–481

7. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395:1054–1062

8. Wu C, Chen X, Cai Y, et al: Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934–943

9. Lassen C, Alois P, Derya A, et al: Out-of-center initiation of venovenous extracorporeal membrane oxygenation in COVID-19 patients. ASAIO J 2020; In Press

10. Barbaro RP, Odetola FO, Kidwell KM, et al: Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med 2015; 191:894–901

11. Falcoz PE, Monnier A, Puyraveau M, et al: Extracorporeal membrane oxygenation for critically ill patients with COVID-19-related acute respiratory distress syndrome: Worth the effort? Am J Respir Crit Care Med 2020; 202:460–463

12. Serpa Neto A, Deliberato RO, Johnson AEW, et al; PROVE Network Investigators: Mechanical power of ventilation is associated with mortality in critically ill patients: An analysis of patients in two observational cohorts. Intensive Care Med 2018; 44:1914–1922

13. Kowalewski M, Fina D, Słomka A, et al: COVID-19 and ECMO: The interplay between coagulation and inflammation— a narrative review. Crit Care 2020; 24:205

14. Jacobs JP, Stammers AH, St Louis J, et al: Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in Coronavirus disease 2019: Experience with 32 patients. ASAIO J 2020; 66:722–730

15. Yang X, Cai S, Luo Y, et al: Extracorporeal membrane oxygenation for Coronavirus disease 2019-induced acute respiratory distress syndrome: A multicenter descriptive study. Crit Care Med 2020; 48:1289–1295